Ruffer LLP Sells 104,917 Shares of IQVIA Holdings Inc. $IQV

Ruffer LLP reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 50.5% during the third quarter, Holdings Channel reports. The firm owned 102,970 shares of the medical research company’s stock after selling 104,917 shares during the period. IQVIA makes up 1.1% of Ruffer LLP’s holdings, making the stock its 29th largest holding. Ruffer LLP’s holdings in IQVIA were worth $19,558,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Verdence Capital Advisors LLC bought a new position in shares of IQVIA in the second quarter valued at approximately $3,612,000. Amundi grew its position in shares of IQVIA by 46.3% during the 2nd quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after purchasing an additional 405,250 shares in the last quarter. Diversified Trust Co increased its holdings in shares of IQVIA by 57.2% in the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after purchasing an additional 15,487 shares during the period. Act Two Investors LLC bought a new stake in IQVIA during the second quarter valued at $26,528,000. Finally, Oregon Public Employees Retirement Fund grew its position in IQVIA by 37.1% during the third quarter. Oregon Public Employees Retirement Fund now owns 19,463 shares of the medical research company’s stock worth $3,697,000 after buying an additional 5,271 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE:IQV opened at $239.67 on Thursday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The business has a 50 day moving average price of $230.48 and a 200-day moving average price of $207.51. The firm has a market cap of $40.82 billion, a PE ratio of 32.88, a price-to-earnings-growth ratio of 2.45 and a beta of 1.36.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.84 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price objective on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. TD Cowen upped their target price on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research report on Thursday, January 22nd. Stifel Nicolaus lifted their price target on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Morgan Stanley increased their price objective on IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. Finally, Citigroup upped their target price on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $251.06.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.